Enzyme immunoassay for the quantitative determination of Tocilizumab (Actemra®) in human serum and plasma.
This kit has been especially developed for the quantitative determination of tocilizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.
Tocilizumab Drug Bank Accession Number is DB06273.
Tocilizumab is an interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact email@example.com
|Required Volume (µl)||10|
|Total Time (min)||70|
|Detection Limit (ng/mL)||3|
|Spike Recovery (%)||Between 85-115|
|Shelf Life (year)||1|
|Storage conditions||Store at +4°C. Please refer to protocols.|
|Shipping conditions||At room temperature|